Top Markets
#1 Helium Helium +116.88%
#2 MowCat MowCat +87.68%
#3 Seeker Seeker +57.76%
#4 UnifAI Network UnifAI Network +33.98%
#5 TENDIES TENDIES +28.85%
#6 pipedog pipedog +22.05%
#7 Zylo Ecosystem Zylo Ecosystem +21.82%
#8 Tensor Tensor +19.08%
#9 Pons Pons +17.58%
#10 MarsCoin MarsCoin +16.53%
Coin of the day
Helium Helium
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
CHO Pharma, Inc. CHO Pharma, Inc.

CHO Pharma, Inc.

6586
Peringkat dalam Saham #11104
CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan,... CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This technology allows for the precise transformation of unconjugated antibodies into either glycoengineered biobetters or ADCs. CHO Pharma boasts a robust and diverse pipeline of drug candidates spanning various therapeutic areas, all leveraging its glycoengineering expertise. Currently, several programs are in clinical development: CHO-H01 is undergoing Phase I/IIa trials for refractory non-Hodgkin lymphoma, while CHO-A04, a humanized monoclonal antibody, has entered Phase I trials targeting a range of tumor and cancer stem cells. Additionally, CHO-V08 is being developed as a vaccine against Klebsiella pneumoniae. In the preclinical stage, CHO Pharma is advancing CHO-H02, an agent designed to address various solid tumors including breast, bladder, pancreatic, ovarian, and gastric cancers. Another preclinical asset, CHO-H03, is an antibody drug being investigated for inflammatory conditions associated with autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Established in 2012, CHO Pharma continues to innovate from its base in Taipei City, Taiwan.
Harga Saham
$3.47
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$741.78M
Perubahan (1 hari)
-0.91%
Perubahan (1 tahun)
181.14%
Negara
TW
Perdagangan CHO Pharma, Inc. (6586)

Kategori

Healthcare
Rasio P/E untuk CHO Pharma, Inc. (6586)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari CHO Pharma, Inc., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk CHO Pharma, Inc. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.